Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.
The Company is currently proceeding with detailed analyses of the data and preparing for a pre-New Drug Application meeting with the U.S. Food and Drug Administration in the upcoming months, which would be followed by the filing of a NDA for the registration of AEZS-130 in the United States.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.